MCID: NDL009
MIFTS: 42

Nodular Basal Cell Carcinoma

Categories: Cancer diseases, Skin diseases

Aliases & Classifications for Nodular Basal Cell Carcinoma

MalaCards integrated aliases for Nodular Basal Cell Carcinoma:

Name: Nodular Basal Cell Carcinoma 12 15
Skin Nodulo-Ulcerative Basal Cell Carcinoma 12
Circumscribed Solid Basal Cell Carcinoma 12
Skin Nodular Solid Basal Cell Carcinoma 71
Nodulo-Ulcerative Basal Cell Carcinoma 71
Skin Solid Basal Cell Carcinoma 12
Skin Nodular Basal Cell Carcinoma 71
Basal Cell Carcinoma, Nodular 12

Classifications:



External Ids:

Disease Ontology 12 DOID:4280
NCIt 49 C62282
UMLS 71 C0862887 C1304300 C1879347

Summaries for Nodular Basal Cell Carcinoma

Disease Ontology : 12 A basal cell carcinoma characterized by elevated, pearl shaped nodules with telengactisae on the surface and periphery.

MalaCards based summary : Nodular Basal Cell Carcinoma, also known as skin nodulo-ulcerative basal cell carcinoma, is related to basal cell carcinoma and skin carcinoma. An important gene associated with Nodular Basal Cell Carcinoma is PRKX (Protein Kinase X-Linked), and among its related pathways/superpathways are Wnt Signaling Pathways: beta-Catenin-dependent Wnt Signaling and Presynaptic function of Kainate receptors. The drugs Imiquimod and Adjuvants, Immunologic have been mentioned in the context of this disorder. Affiliated tissues include skin, lymph node and breast.

Related Diseases for Nodular Basal Cell Carcinoma

Graphical network of the top 20 diseases related to Nodular Basal Cell Carcinoma:



Diseases related to Nodular Basal Cell Carcinoma

Symptoms & Phenotypes for Nodular Basal Cell Carcinoma

Drugs & Therapeutics for Nodular Basal Cell Carcinoma

Drugs for Nodular Basal Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 25)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Imiquimod Approved, Investigational Phase 4 99011-02-6 57469
2 Adjuvants, Immunologic Phase 4
3 Immunologic Factors Phase 4
4 Interferon Inducers Phase 4
5 interferons Phase 4
6
Aminolevulinic acid Approved Phase 3 106-60-5 137
7 Methyl 5-aminolevulinate Phase 3
8 Dermatologic Agents Phase 3
9 Photosensitizing Agents Phase 3
10 Anesthetics Phase 3
11
Fluorouracil Approved Phase 1, Phase 2 51-21-8 3385
12
Cisplatin Approved Phase 1, Phase 2 15663-27-1 84093 441203 2767
13 Immunosuppressive Agents Phase 1, Phase 2
14 Antimetabolites Phase 1, Phase 2
15 Interferon-gamma Phase 1, Phase 2
16 Pharmaceutical Solutions Phase 1, Phase 2
17
Doxorubicin Approved, Investigational Phase 1 23214-92-8 31703
18 Anti-Bacterial Agents Phase 1
19 Antibiotics, Antitubercular Phase 1
20 Topoisomerase Inhibitors Phase 1
21
Liposomal doxorubicin Phase 1 31703
22
Epinephrine Approved, Vet_approved 51-43-4 5816
23
Lidocaine Approved, Vet_approved 137-58-6 3676
24
Racepinephrine Approved 329-65-7 838
25 Epinephryl borate

Interventional clinical trials:

(show all 19)
# Name Status NCT ID Phase Drugs
1 Topical Imiquimod 5% Cream in the Treatment of Nodular Basal Cell Carcinoma After Initial Treatment With Curettage Completed NCT00314756 Phase 4 imiquimod
2 A Randomized Open Label Study to Evaluate the Safety and Efficacy if Imiquimod 5% Cream Applied 3 Times Per Week for 8 or 12 Weeks in the Treatment of Low Risk Nodular Basal Cell Carcinoma Completed NCT00204555 Phase 4 Imiquimod
3 A Multicenter, Phase III, Double Blind Study of Photodynamic Therapy (PDT) With Metvix 160 mg/g Cream in Comparison to PDT With Placebo Cream in Patients With Primary Nodular Basal Cell Carcinoma Completed NCT00472108 Phase 3
4 A Multicentre, Phase III, Double Blind Study of Photodynamic Therapy (PDT) With Metvix® 160 mg/g Cream in Comparison to PDT With Placebo Cream in Patients With Primary Nodular Basal Cell Carcinoma. Completed NCT00472043 Phase 3
5 Surgical Excision Versus Combined Treatment With Curettage and Imiquimod for Nodular Basal Cell Carcinoma: an Open, Non-inferiority, Randomized Controlled Trial Active, not recruiting NCT02242929 Phase 3 Imiquimod 5% cream with prior curettage
6 Investigation of the Effectiveness of Non-Coherent Blue Light in Intralesional Photodynamic of Basal Cell Carcinoma Unknown status NCT00747903 Phase 2 aminolevulinic acid hydrochloride
7 A Multi-center, Randomized, Double-blind, Parallel-group, Vehicle-controlled Study to Determine the Safety of PEP005 0.0025%, 0.01% and 0.05% Gel With Two Treatment Schedules, Day 1 & 2 or Day 1 & 8 Applications to Nodular Basal Cell Carcinoma Completed NCT00108121 Phase 2 PEP005
8 A Phase 1/2a Study of the Efficacy and Safety of ASN-002 Alone or in Combination With 5-FU in Adult Patients With Low-risk Nodular Basal Cell Carcinoma Completed NCT02550678 Phase 1, Phase 2 5-FU
9 Investigation of Local Skin Reactions and Safety After Combined Treatment of Basal Cell Carcinoma Using Ablative Fractional Laser and Ingenol Mebutate - an Exploratory, Prospective, Open-label Phase 2a Trial. Completed NCT03569345 Phase 1, Phase 2 AFXl-assisted ingenol mebutate delivery
10 Tolerability of Laser-assisted Cisplatin + 5-fluorouracil― an Exploratory Proof of Concept Study of Topical Combination Chemotherapy for Basal Cell Carcinoma Recruiting NCT03541252 Phase 1, Phase 2 AFL-assisted cisplatin+5-FU
11 Bi-center, Open Label, Non-comparative Trial Exploring Efficacy and Safety of Topical Resiquimod Gel (0.06%) in Patients With Nodular Basal Cell Carcinoma (nBCC) Terminated NCT01808950 Phase 1, Phase 2 0.06% Resiquimod Gel - A;0.06% Resiquimod Gel - B;0.06% Resiquimod Gel - C
12 Er:YAG Ablative Fractional Laser Assisted-Photodynamic Therapy Versus Photodynamic Therapy for Nodular Basal Cell Carcinoma in Asian: A Prospective, Randomized Study With 12 Months Follow-up Completed NCT02018679 Phase 1
13 An Open-Label Dose Escalation Trial to Evaluate Dose Limiting Toxicity (DLT), Maximum Tolerated Dose (MTD), Safety, and Tolerability of Microneedle Arrays Containing Doxorubicin (D-MNA) in Participants With Basal Cell Carcinoma (BCC) Recruiting NCT03646188 Phase 1 Placebo-containing MNA;25 µg doxorubicin-containing MNA;50 µg doxorubicin-containing MNA;100 µg doxorubicin-containing MNA;200 µg doxorubicin-containing MNA
14 Melanocyte Features and Its Influence in Pigmentation in Basal Cell Carcinoma in the Mexican Population Unknown status NCT02576769
15 A Randomised Study Comparing Tissue Conservation in Conventional Versus Mohs' Surgery of Basal Cell Carcinoma Completed NCT00571363
16 A Randomized Controlled Blinded Multi-centre Study of Photodynamic Therapy With Methyl-aminolevulinate Comparing a Simplified Regime With the Approved Regime in Patients With Clinical Low-risk Superficial and Nodular Basal Cell Carcinoma. Completed NCT01482104 MAL-PDT re-treatment;usual MAL-PDT
17 Randomized Pilot Study of Treatment for Basal Cell Carcinoma Using the Multiplex 595/1064 nm Laser Completed NCT02270645
18 Sentinel Lymph Node Biopsy in Porocarcinoma: A Case Reports Completed NCT03647631
19 Clinical Diagnosis Versus Histological Diagnosis by Punch Biopsy to Determine the Subtype of Basal Cell Carcinoma Completed NCT01370824

Search NIH Clinical Center for Nodular Basal Cell Carcinoma

Genetic Tests for Nodular Basal Cell Carcinoma

Anatomical Context for Nodular Basal Cell Carcinoma

MalaCards organs/tissues related to Nodular Basal Cell Carcinoma:

40
Skin, Lymph Node, Breast, B Cells

Publications for Nodular Basal Cell Carcinoma

Articles related to Nodular Basal Cell Carcinoma:

(show top 50) (show all 191)
# Title Authors PMID Year
1
[Young male patient with unusual space-occupying lesion of the lower eyelid]. 61
31359135 2020
2
Cutaneous neoplasms composed of melanoma and carcinoma: A rare but important diagnostic pitfall and review of the literature. 61
31361351 2020
3
Multispectral near infrared absorption imaging for histology of skin cancer. 61
31602799 2020
4
European Dermatology Forum guidelines on topical photodynamic therapy 2019 Part 1: treatment delivery and established indications - actinic keratoses, Bowen's disease and basal cell carcinomas. 61
31779042 2019
5
Use of dermograph for improvement of PpIX precursor's delivery in Photodynamic Therapy: experimental and clinical pilot studies. 61
31731063 2019
6
Photodynamic therapy: A targeted literature review focussing on outcomes and optimisation in solid organ transplant recipients. 61
31012102 2019
7
Basal Cell Carcinoma Originating in a Tattoo: Case Report and Review of an Uncommon Complication in Tattoo Recipients. 61
31723458 2019
8
High-frequency ultrasound in the diagnosis of selected non-melanoma skin nodular lesions. 61
31839774 2019
9
Utilization of optical coherence tomography as a noninvasive, bedside imaging technique to identify residual nodular basal cell carcinoma at a well-healed and clinically unidentifiable biopsy site. 61
30771419 2019
10
Excision of nodular basal cell carcinoma involving the lower eyelid tarsal skin using a grey line-splitting, posterior lamella-sparing technique. 61
29461902 2019
11
Skin cancer incidence in rural workers at a reference hospital in western Paraná. 61
31090820 2019
12
Basal Cell Carcinoma Associated with Secondary Localized Cutaneous Amyloid Deposits: Case Report and Review. 61
30899630 2019
13
Dermoscopy Patterns and Histopathological Findings in Nodular Basal Cell Carcinoma-Study on 68 Cases. 61
31297272 2019
14
Ultrasonographic features of superficial and nodular basal cell carcinoma. 61
30534655 2018
15
A systematic review on the use of cryotherapy versus other treatments for basal cell carcinoma. 61
30695972 2018
16
Intradermal Delivery of a Near-Infrared Photosensitizer Using Dissolving Microneedle Arrays. 61
29864428 2018
17
Solitary plantar basal cell carcinoma. 61
29924227 2018
18
Nodular basal cell carcinoma of the face successfully treated with ingenol mebutate 0.015% gel. 61
29785331 2018
19
Eyelid Reconstruction: Pediculated versus Non-Pediculated. 61
29351708 2018
20
Analysis of hedgehog signaling in periocular sebaceous carcinoma. 61
29423837 2018
21
An Experimental and Numerical Study on Nodular Gel Phantom during Cryotherapy. 61
29734423 2018
22
Programmed Death-1 Pathway in Orbital Invasion of Cutaneous Carcinomas. 61
28350690 2018
23
Assessment of singlet oxygen dosimetry concepts in photodynamic therapy through computational modeling. 61
29292205 2018
24
Macrophage subtypes in recurrent nodular basal cell carcinoma after Mohs micrographic surgery. 61
28994114 2017
25
Superiorly based nasolabial island flap for reconstruction of the lateral lower eyelid 61
29306222 2017
26
Dynamic thiol/disulphide homeostasis in patients with basal cell carcinoma. 61
28067074 2017
27
Injectable Diphenhydramine Used as Anaesthetic for Wide Local Excision With Flap Closure. 61
27920067 2017
28
Basal Cell Carcinoma Arising in a Breast Augmentation Scar. 61
28130559 2017
29
Surgery Versus 5% Imiquimod for Nodular and Superficial Basal Cell Carcinoma: 5-Year Results of the SINS Randomized Controlled Trial. 61
27932240 2017
30
A rare dermoscopic pattern of nodular basal cell carcinoma with amyloid deposition. 61
28087032 2017
31
Auricular Hemosiderosis in a Diabetic Patient. 61
28859747 2017
32
Imiquimod 5% cream for the treatment of large nodular basal cell carcinoma at the medial canthal area. 61
28300740 2017
33
A Multicenter Clinical Study of Expected and Unexpected Side Reactions During and After Skin Cancer Treatment by Photodynamic Therapy. 61
28528604 2017
34
Photodynamic therapy versus surgical excision to basal cell carcinoma: meta-analysis. 61
27363535 2016
35
A retrospective study on the effectiveness of curettage and electrodesiccation for clinically suspected primary nodular basal cell carcinoma. 61
27229620 2016
36
An Interesting Case of Basal Cell Carcinoma with Raynaud's Phenomenon Following Chronic Arsenic Exposure. 61
28029677 2016
37
Altered Expression of PRKX, WNT3 and WNT16 in Human Nodular Basal Cell Carcinoma. 61
27630294 2016
38
[Development of a PCR for the detection and quantification of parasitism by Demodex folliculorum infestation in biopsies of skin neoplasms periocular area]. 61
27305511 2016
39
The effect of topical diclofenac 3% and calcitriol 3 μg/g on superficial basal cell carcinoma (sBCC) and nodular basal cell carcinoma (nBCC): A phase II, randomized controlled trial. 61
27067393 2016
40
Fibroepithelioma of Pinkus in continuity with nodular basal cell carcinoma: A rare presentation. 61
27559504 2016
41
Fibroepithelioma of Pinkus in continuity with a pigmented nodular basal cell carcinoma (BCC): A dermoscopic and histologic correlation. 61
27085246 2016
42
Er:YAG ablative fractional laser-primed photodynamic therapy with methyl aminolevulinate as an alternative treatment option for patients with thin nodular basal cell carcinoma: 12-month follow-up results of a randomized, prospective, comparative trial. 61
26551044 2016
43
Daylight photodynamic therapy with methyl aminolaevulinate in patients with actinic keratoses: a preliminary experience in Southern Italy. 61
25279493 2016
44
Aminolevulinic acid and methyl aminolevulinate equally effective in topical photodynamic therapy for non-melanoma skin cancers. 61
26841041 2016
45
Electronic brachytherapy for superficial and nodular basal cell carcinoma: a report of two prospective pilot trials using different doses. 61
26985197 2016
46
Imiquimod 5% as Adjuvant Therapy for Incompletely Excised Infiltrative Nodular Basal Cell Carcinoma and Dermoscopy to Monitor Treatment Response. 61
26538104 2015
47
Dermoscopic Findings in Trichoblastoma. 61
26032870 2015
48
A phase II, multicenter, open-label, 3-cohort trial evaluating the efficacy and safety of vismodegib in operable basal cell carcinoma. 61
25913533 2015
49
European Dermatology Forum Guidelines on topical photodynamic therapy. 61
26065545 2015
50
Efficacy and safety of electronic brachytherapy for superficial and nodular basal cell carcinoma. 61
26207112 2015

Variations for Nodular Basal Cell Carcinoma

Cosmic variations for Nodular Basal Cell Carcinoma:

9 (show top 50) (show all 3424)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM149268805 ZFHX3 skin,NS,carcinoma,basal cell carcinoma c.1261G>A p.G421R 16:72958885-72958885 12
2 COSM149259613 ZFHX3 skin,NS,carcinoma,basal cell carcinoma c.10847C>T p.S3616F 16:72787429-72787429 12
3 COSM149268792 ZFHX3 skin,NS,carcinoma,basal cell carcinoma c.5825G>A p.G1942E 16:72796857-72796857 12
4 COSM149268800 ZFHX3 skin,NS,carcinoma,basal cell carcinoma c.1655C>T p.S552F 16:72958491-72958491 12
5 COSM149304906 ZFHX3 skin,NS,carcinoma,basal cell carcinoma c.1991C>T p.S664F 16:72958155-72958155 12
6 COSM149331772 ZFHX3 skin,NS,carcinoma,basal cell carcinoma c.11050G>A p.D3684N 16:72787226-72787226 12
7 COSM149266372 ZFHX3 skin,NS,carcinoma,basal cell carcinoma c.2084C>T p.P695L 16:72958062-72958062 12
8 COSM101976974 XPO1 skin,NS,carcinoma,basal cell carcinoma c.782G>A p.R261Q 2:61496985-61496985 12
9 COSM87040659 TSC2 skin,NS,carcinoma,basal cell carcinoma c.869C>T p.P290L 16:2058767-2058767 12
10 COSM87027025 TSC2 skin,NS,carcinoma,basal cell carcinoma c.2060C>T p.S687F 16:2071897-2071897 12
11 COSM87028684 TSC2 skin,NS,carcinoma,basal cell carcinoma c.679T>A p.C227S 16:2056674-2056674 12
12 COSM90144180 TRAF7 skin,NS,carcinoma,basal cell carcinoma c.1802C>T p.T601I 16:2176104-2176104 12
13 COSM88644633 TP63 skin,NS,carcinoma,basal cell carcinoma c.1922C>T p.A641V 3:189894381-189894381 12
14 COSM87925664 TP53 skin,NS,carcinoma,basal cell carcinoma c.477C>T p.A159= 17:7675135-7675135 12
15 COSM87919454 TP53 skin,NS,carcinoma,basal cell carcinoma c.395A>T p.K132M 17:7675217-7675217 12
16 COSM88272290 TP53 skin,NS,carcinoma,basal cell carcinoma c.480G>C p.M160I 17:7675132-7675132 12
17 COSM87898709 TP53 skin,NS,carcinoma,basal cell carcinoma c.742C>T p.R248W 17:7674221-7674221 12
18 COSM87910628 TP53 skin,NS,carcinoma,basal cell carcinoma c.772G>A p.E258K 17:7674191-7674191 12
19 COSM88387703 TP53 skin,NS,carcinoma,basal cell carcinoma c.781A>T p.S261C 17:7674182-7674182 12
20 COSM87963219 TP53 skin,NS,carcinoma,basal cell carcinoma c.292C>T p.P98S 17:7676077-7676077 12
21 COSM87929396 TP53 skin,NS,carcinoma,basal cell carcinoma c.530C>T p.P177L 17:7675082-7675082 12
22 COSM87898723 TP53 skin,NS,carcinoma,basal cell carcinoma c.817C>T p.R273C 17:7673803-7673803 12
23 COSM88310572 TP53 skin,NS,carcinoma,basal cell carcinoma c.677G>C p.G226A 17:7674286-7674286 12
24 COSM87898714 TP53 skin,NS,carcinoma,basal cell carcinoma c.844C>T p.R282W 17:7673776-7673776 12
25 COSM87898991 TP53 skin,NS,carcinoma,basal cell carcinoma c.535C>T p.H179Y 17:7675077-7675077 12
26 COSM88408340 TP53 skin,NS,carcinoma,basal cell carcinoma c.899C>G p.P300R 17:7673721-7673721 12
27 COSM87906968 TP53 skin,NS,carcinoma,basal cell carcinoma c.833C>T p.P278L 17:7673787-7673787 12
28 COSM87910495 TP53 skin,NS,carcinoma,basal cell carcinoma c.832C>T p.P278S 17:7673788-7673788 12
29 COSM87899497 TP53 skin,NS,carcinoma,basal cell carcinoma c.586C>T p.R196* 17:7674945-7674945 12
30 COSM87906130 TP53 skin,NS,carcinoma,basal cell carcinoma c.854A>T p.E285V 17:7673766-7673766 12
31 COSM87919200 TP53 skin,NS,carcinoma,basal cell carcinoma c.511G>C p.E171Q 17:7675101-7675101 12
32 COSM87944274 TP53 skin,NS,carcinoma,basal cell carcinoma c.419C>T p.T140I 17:7675193-7675193 12
33 COSM87921224 TP53 skin,NS,carcinoma,basal cell carcinoma c.835G>A p.G279R 17:7673785-7673785 12
34 COSM87898567 TP53 skin,NS,carcinoma,basal cell carcinoma c.748C>T p.P250S 17:7674215-7674215 12
35 COSM87900980 TP53 skin,NS,carcinoma,basal cell carcinoma c.839G>A p.R280K 17:7673781-7673781 12
36 COSM87947692 TP53 skin,NS,carcinoma,basal cell carcinoma c.770T>C p.L257P 17:7674193-7674193 12
37 COSM87957813 TP53 skin,NS,carcinoma,basal cell carcinoma c.737T>G p.M246R 17:7674226-7674226 12
38 COSM87904406 TP53 skin,NS,carcinoma,basal cell carcinoma c.796G>A p.G266R 17:7673824-7673824 12
39 COSM87917387 TP53 skin,NS,carcinoma,basal cell carcinoma c.746G>C p.R249T 17:7674217-7674217 12
40 COSM87932688 TP53 skin,NS,carcinoma,basal cell carcinoma c.507G>A p.M169I 17:7675105-7675105 12
41 COSM87903307 TP53 skin,NS,carcinoma,basal cell carcinoma c.841G>A p.D281N 17:7673779-7673779 12
42 COSM87905687 TP53 skin,NS,carcinoma,basal cell carcinoma c.955A>G p.K319E 17:7673573-7673573 12
43 COSM87899661 TP53 skin,NS,carcinoma,basal cell carcinoma c.797G>A p.G266E 17:7673823-7673823 12
44 COSM87908365 TP53 skin,NS,carcinoma,basal cell carcinoma c.454C>T p.P152S 17:7675158-7675158 12
45 COSM87961406 TP53 skin,NS,carcinoma,basal cell carcinoma c.532C>A p.H178N 17:7675080-7675080 12
46 COSM87918616 TP53 skin,NS,carcinoma,basal cell carcinoma c.993+1G>A p.? 17:7673534-7673534 12
47 COSM87897745 TP53 skin,NS,carcinoma,basal cell carcinoma c.524G>A p.R175H 17:7675088-7675088 12
48 COSM87911563 TP53 skin,NS,carcinoma,basal cell carcinoma c.388C>T p.L130F 17:7675224-7675224 12
49 COSM87922049 TP53 skin,NS,carcinoma,basal cell carcinoma c.713G>T p.C238F 17:7674250-7674250 12
50 COSM87898431 TP53 skin,NS,carcinoma,basal cell carcinoma c.451C>T p.P151S 17:7675161-7675161 12

Expression for Nodular Basal Cell Carcinoma

Search GEO for disease gene expression data for Nodular Basal Cell Carcinoma.

Pathways for Nodular Basal Cell Carcinoma

GO Terms for Nodular Basal Cell Carcinoma

Cellular components related to Nodular Basal Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 intermediate filament GO:0005882 8.8 KRT38 KRT15 BFSP1

Biological processes related to Nodular Basal Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell fate commitment GO:0045165 9.16 WNT3 WNT16
2 hyaluronan catabolic process GO:0030214 8.96 HYAL3 HMMR
3 keratinocyte proliferation GO:0043616 8.62 WNT16 PTCH1

Molecular functions related to Nodular Basal Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 frizzled binding GO:0005109 8.62 WNT3 WNT16

Sources for Nodular Basal Cell Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....